Table 4 |
|||||
|
Estimates for cost and utility model variables |
|||||
| Health states (Visual acuity measured in letters read) |
|||||
| 90 |
75 |
60 |
45 |
≤ 30 |
|
|
|
|||||
| Annual costs* |
|||||
| Medical care |
|||||
| AMD -related† |
$645 |
$645 |
$645 |
$645 |
$645 |
| Non eye-related‡ |
- |
- |
$2,288 |
$2,288 |
$3,445 |
| Total medical care |
$645 |
$645 |
$2,933 |
$2,933 |
$4,090 |
| Caregivers§ |
- |
$795 |
$3,625 |
$14,185 |
$47,086 |
| Total |
$645 |
$1,440 |
$6,558 |
$17,118 |
$51,176 |
| Utility values¶ |
|||||
| 0.89 |
0.89 |
0.81 |
0.57 |
0.52 |
|
|
|
|||||
|
* 2004 U.S. dollars † AMD = age-related macular degeneration. Excluding costs of ranibizumab acquisition and administration. Source: Halpern et al.[15] ‡ Source: Javitt et al.[16] §Source: Schmier et al.[17] ¶Source: Brown et al.[18] |
|||||
|
Hurley et al. Cost Effectiveness and Resource Allocation 2008 6:12 doi:10.1186/1478-7547-6-12 |
|||||